BCR-ABL tyrosine kinase inhibitors (TKI) are able to induce remission in CML patients but not to eliminate leukemia stem cells (LSC), which can regenerate leukemia on drug discontinuation [2–4]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.